Policy· August 21, 2026 · 19 min read
Reject China Trial Data Without Audits: What the Moolenaar Letter Would Do
By Ran Chen#Clinical Trials#Regulatory#China
Topic
China
China pharmaceutical market, NMPA regulation, API sourcing from China, China Plus One strategy, and BIOSECURE Act impacts.
Policy· August 7, 2026 · 14 min read
EUDAMED mandatory 2026: EU device database scale, actors, and MDR deadlines
By Ran Chen#Policy#Regulatory#Supply Chain
Global· July 20, 2026 · 17 min read
FDA-registered device establishments by country (2026)
By Ran Chen#Supply Chain#China#BIOSECURE Act
Pricing & Access· June 30, 2026 · 18 min read
China's 2026 Dual-Track Drug Catalog: Reading NHSA Preliminary Numbers
By Ran Chen#China#Market Access#Drug Pricing
Policy· June 30, 2026 · 18 min read
China Drug Trial Data Protection (NMPA 2026 No.47): Exclusivity and BD Strategy
By Ran Chen#China#NMPA#Regulatory
Policy· June 30, 2026 · 18 min read
China's 2026 Medical Representative Measures: Building a Compliant Model
By Ran Chen#China#NMPA#Market Access
Policy· June 8, 2026 · 11 min read